Arrowhead Pharmaceuticals (ARWR) vs Cytokinetics (CYTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Cytokinetics (CYTK) over the past year, gaining 68.3% versus a gain of 1.6%. Over five years, CYTK leads with a +65.7% price change compared with -7.1% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($8.68 billion vs $8.50 billion), about 1.0 times the size.
Arrowhead Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.2% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | CYTK |
|---|---|---|
| Share price | $61.48 | $61.12 |
| Market cap | $8.68B | $8.50B |
| 1-day change | -0.10% | -0.37% |
| YTD return | -7.40% | -3.81% |
| 1-year return | +68.25% | +1.58% |
| 5-year return | -7.07% | +65.68% |
| EPS (TTM) | $-2.28 | $-7.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $88.04M |
| Revenue growth (YoY) | +23258.15% | +376.56% |
| Net income (latest FY) | $-1.63M | $-784.96M |
| Operating margin | 11.86% | -695.44% |
| Net margin | -0.20% | -891.60% |
| 52-week high | $95.49 | $88.31 |
| 52-week low | $34.61 | $54.30 |
| Distance from 52-week high | -35.62% | -30.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +74.41% | +79.81% |
| Average volume | 1.90M | 1.96M |
| Shares outstanding | 141.25M | 139.02M |
| Employees | 711 | 673 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed CYTK by 66.7 percentage points over the past year.
- Arrowhead Pharmaceuticals is more profitable, keeping -0.2 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +376.56%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
ARWR vs CYTK FAQ
Which is bigger, Arrowhead Pharmaceuticals or Cytokinetics?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $8.68B compared with $8.50B for Cytokinetics (CYTK).
Which stock has performed better over the past year, ARWR or CYTK?
ARWR returned +68.25% over the past 12 months, compared with +1.58% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Cytokinetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.